The Historical Evolution of Peking University Pharmaceutical Co., Ltd.

Peking University Pharmaceutical Co., Ltd. (formerly known as Peking University International Hospital Group Southwest synthesis of pharmaceuticals Co., Ltd., renamed Peking University Pharmaceutical Co., Ltd. on October 20165438+/KLOC-0, hereinafter referred to as the company or the company) was approved by Chongqing Economic System Reform Commission on May 1938+08, and was established by Southwest Synthetic Pharmaceutical Factory (now Southwest synthesis of pharmaceuticals Group) Formerly known as Southwest synthesis of pharmaceuticals General Factory), with its net assets of 85 million yuan as the consideration (the share conversion ratio is 1: 1), and at the same time, it issues 45 million legal person shares to social legal persons at a fair price, and is established by directional issuance.

1997 In May, the company issued 45 million public shares (A shares) with the approval of China Securities Regulatory Commission Jian Zheng Fa Zi (1997) No.238 and Jian Zheng Fa Zi (1997) No.239. In June, 1997. According to the annual profit distribution plan of 1997 adopted by the company's shareholders' meeting, for every 10 share 1 share, the company's shares increased to192.5 million shares. On April 20, 2006, according to the resolution of the first extraordinary shareholders' meeting in 2006 and the document No.335 of the State Council State-owned Assets Supervision and Administration Commission, the company transferred 24,799,500 shares (49,500,000 shares) to all tradable shareholders by increasing 5,065,438+0 shares for every 65,438+00 shares.

On May 27th, 2009, with the approval of China Securities Regulatory Commission's document No.435 [2009] of Jian Zheng Securities Regulatory Commission, the company issued 42,872,365,438+065,438+0 yuan RMB ordinary shares (par value of 65,438+0 yuan per share) to Peking University Pharmaceutical Industry Group Co., Ltd. Purchased 90.63% equity of Chongqing Daxin 20 10, 18. According to the resolution of the company's annual general meeting in 2009, the company transferred15,6103086 shares to all shareholders with capital reserve, and the company's shares increased to 4/kloc-0. On February 25th, 20 1 1, according to the resolution of the company's 20 10 annual general meeting, the company distributed 4 bonus shares for every 10 share, distributed cash 1.00 yuan and distributed bonus shares 16 shares.

On September 20th, 20 1 1, it was approved by China Securities Regulatory Commission [2011]151/and was the fifth temporary shareholder of the company in 201. 202,570 shares (par value 65,438+0 yuan per share, issue price 65,438+00.26 yuan per share), and purchased 65,438+000% equity of Beijing Yi Bei Pharmaceutical Co., Ltd. After this issuance, the company's shares increased to 595,987,425 shares.